How have SGIOF shares performed in 2024?

Shionogi & Co., Ltd.'s stock was trading at $46.21 on January 1st, 2024. Since then, SGIOF shares have increased by 3.5% and is now trading at $47.8250. View the best growth stocks for 2024 here .

Are investors shorting Shionogi & Co., Ltd.?

Shionogi & Co., Ltd. saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 296,600 shares, a decline of 20.7% from the April 15th total of 374,100 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 2,966.0 days. View Shionogi & Co., Ltd.'s Short Interest .

Is Shionogi & Co., Ltd. a good dividend stock?

Shionogi & Co., Ltd. (OTCMKTS:SGIOF) pays an annual dividend of $19.10 per share and currently has a dividend yield of 1.14%. The dividend payout ratio is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:SGIOF

Shionogi & Co., Ltd. (SGIOF) Stock Price, News & Analysis

→ Elon to Transform U.S. Economy? (From Porter & Company) (Ad)

Free SGIOF Stock Alerts

$47.83

0.00 (0.00%)

(As of 05/16/2024 ET)

Compare

Today's Range: $47.83
▼
$47.83
50-Day Range: $47.83
▼
$53.50
52-Week Range: $40.46
▼
$53.50

Volume: 200 shs
Average Volume: 540 shs
Market Capitalization: N/A

P/E Ratio: 0.53
Dividend Yield: 39.94%
Price Target: N/A

Stock Analysis Chart Financials SEC Filings Short Interest

Get Shionogi & Co., Ltd. alerts:

Shionogi & Co., Ltd. MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.99
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.53 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Shionogi & Co., Ltd..
Read more about Shionogi & Co., Ltd.'s stock forecast and price target.

2.0

Short Interest

Percentage of Shares Shorted
Short Interest Ratio / Days to Cover
Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 2966, which indicates bearish sentiment.
Change versus previous month
Short interest in Shionogi & Co., Ltd. has recently decreased by 20.72%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
Shionogi & Co., Ltd. pays a meaningful dividend of 1.14%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Shionogi & Co., Ltd. does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Shionogi & Co., Ltd. is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.
Read more about Shionogi & Co., Ltd.'s dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SGIOF.

2.2

News and Social Media Coverage

News Sentiment
Shionogi & Co., Ltd. has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Shionogi & Co., Ltd. this week, compared to 3 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 22.59% of the stock of Shionogi & Co., Ltd. is held by institutions.
Read more about Shionogi & Co., Ltd.'s insider trading history.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Shionogi & Co., Ltd. is 0.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.13.
Price to Earnings Ratio vs. Sector
The P/E ratio of Shionogi & Co., Ltd. is 0.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 170.77.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Biden FINISHED On June 13th?

Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.

Click here now to see his shocking evidence.

About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOF)

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

SGIOF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SGIOF Stock News Headlines

May 12, 2024 | americanbankingnews.com

Shionogi & Co., Ltd. (OTCMKTS:SGIOF) Short Interest Down 20.7% in April

May 8, 2024 | americanbankingnews.com

Shionogi & Co., Ltd. (OTCMKTS:SGIOF) Trading Down 3.6%

May 16, 2022 | finance.yahoo.com

Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

March 25, 2022 | seekingalpha.com

Shionogi inks supply deal with Japanese government for oral COVID drug S-217622

March 4, 2022 | seekingalpha.com

Shionogi COVID-19 vaccine meets primary endpoint as booster

September 29, 2021 | msn.com

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive

See More Headlines

Receive SGIOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: OTCMKTS:SGIOF
CUSIP: N/A
CIK: 1281721
Web: www.shionogi.co.jp
Phone: (166) 202-2161
Fax: N/A
Employees: 5,680
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 0.53
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Isao Teshirogi Ph.D. (Age 65)
CEO, President & Representative Director
Comp: $1.9M
Susumu Mitsumori
Vice President of Finance & Accounting Department
Mr. Kazuhiro Hatanaka
Senior Executive Officer & Senior VP of Administration Division
Mr. Takeshi Shiota Ph.D.
Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.
Mr. Yoshimasa Kyokawa
Vice President of Corporate Communications & Secretary Office
Yoshihiro Furuya
Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office
Mr. Kohji Hanasaki Ph.D.
Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business Division
Dr. John A. Keller Ph.D. (Age 59)
Senior Executive Officer and Senior VP of R&D Supervisory Unit
Akira Kato Ph.D.
Corporate Officer & President of Shionogi Pharma Co., Ltd
Dr. Ryuichi Kiyama Ph.D.
Senior Executive Officer & Senior VP of Corporate Strategy Division

Key Competitors

View All Competitors

SGIOF Stock Analysis - Frequently Asked Questions

How have SGIOF shares performed in 2024?: Shionogi & Co., Ltd.'s stock was trading at $46.21 on January 1st, 2024. Since then, SGIOF shares have increased by 3.5% and is now trading at $47.8250.
View the best growth stocks for 2024 here.
Are investors shorting Shionogi & Co., Ltd.?: Shionogi & Co., Ltd. saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 296,600 shares, a decline of 20.7% from the April 15th total of 374,100 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 2,966.0 days.
View Shionogi & Co., Ltd.'s Short Interest.
Is Shionogi & Co., Ltd. a good dividend stock?: Shionogi & Co., Ltd. (OTCMKTS:SGIOF) pays an annual dividend of $19.10 per share and currently has a dividend yield of 1.14%. The dividend payout ratio is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.
How do I buy shares of Shionogi & Co., Ltd.?: Shares of SGIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SGIOF) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Shionogi & Co., Ltd. (SGIOF) Stock Price, News & Analysis